Literature DB >> 16188956

Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines.

Jie Su1, Li He, Ningning Zhang, Paul C Ho.   

Abstract

The tributyrin lipid emulsion was proved to be able to bind to low-density lipoprotein (LDL) in vitro. The aim of this study was to investigate the pharmacokinetics of the emulsion in vivo and the cellular activity in vitro. The pharmacokinetics of tributyrin and its metabolite, butyrate, was evaluated in male Wistar rats after administration with pure tributyrin or tributyrin emulsion. After oral administration, maximal plasma concentration (C(max)), time to reach maximal plasma concentration (T(max)), and elimination half-life (T(1/2)) of butyrate were 87.6 muM and 25.3 and 63.0 min, respectively, for the pure tributyrin compared with 1344.5 microM and 8.5 and 19.8 min for the 10% (v/v) tributyrin emulsion. C(max) and mean residence time of tributyrin were 2.74 microM and 87.9 min and 4.2 microM and 132.0 min for pure tributyrin and 10% emulsion, respectively. The bioavailabilities of the pure tributyrin versus tributyrin emulsion were 15.3 versus 65.7% and 34.9 versus 64.5% calculated from butyrate and tributyrin, respectively. After the rats were treated with 17alpha-ethynylestradiol (an LDL receptor up-regulator), the distribution volumes calculated from both butyrate and tributyrin were significantly increased after oral administration or infusion of the 10% tributyrin emulsion. The increased distribution volume after coadministration with a LDL receptor up-regulator suggested the increased uptake of tributyrin/butyrate by tissues with increased expression of LDL receptors. The selective uptake of the emulsion by the cellular LDL receptors was further confirmed by testing the cellular viability in the presence of competing LDL. The viable cells can reach 92% of control at IC(50) in Caco-2 and 77% in HepG2 incubated with emulsion in the presence of LDL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188956     DOI: 10.1124/jpet.105.090464

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predicts Partitioning and Pharmacokinetics.

Authors:  Ray R Zhang; Joseph J Grudzinksi; Tej I Mehta; Ronald R Burnette; Reinier Hernandez; Paul A Clark; Jonathan A Lubin; Anatoly N Pinchuk; Justin Jeffrey; Marc Longino; John S Kuo; Jamey P Weichert
Journal:  Mol Pharm       Date:  2019-07-08       Impact factor: 4.939

2.  Dietary Tributyrin Supplementation Attenuates Insulin Resistance and Abnormal Lipid Metabolism in Suckling Piglets with Intrauterine Growth Retardation.

Authors:  Jintian He; Li Dong; Wen Xu; Kaiwen Bai; Changhui Lu; Yanan Wu; Qiang Huang; Lili Zhang; Tian Wang
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

3.  Monobutyrin Reduces Liver Cholesterol and Improves Intestinal Barrier Function in Rats Fed High-Fat Diets.

Authors:  Thao Duy Nguyen; Olena Prykhodko; Frida F Hållenius; Margareta Nyman
Journal:  Nutrients       Date:  2019-02-01       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.